Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, and Attending Physician, Pediatric Emergency Medicine, Nemours/Alfred I duPont ...
This episode bridges the gap between clinical trial data and everyday practice, focusing on how pediatricians can systematically ensure no eligible infant falls through the cracks. This episode ...
The July 1, 2026 decision makes exagamglogene autotemcel the first gene therapy approved for SCD in children younger than 12 years. The FDA has issued a supplemental approval for Casgevy ...
The AAP now recommends universal iron deficiency screening for all infants between 9 and 18 months and for all adolescents at least 1 year after menarche but no later than age 14. Updated ferritin ...
New RSV shots and monoclonals cut infant hospitalizations up to 85%, with strong real‑world safety—learn what efficacy vs effectiveness really means. This episode provides a clear-eyed analysis of ...
In this episode, Dr. Simões reviews the post-licensure landscape, highlighting data from real-world effectiveness studies now emerging from multiple countries. Initial real-world data for one ...
The PANDAS/PANS questionnaire is based on symptoms and comorbidities described in the literature and is a self-report completed by parents of children younger than 18. "Bottom line, previous surgery ...
Researchers found evidence that childhood influences may contribute to 85 adult health diagnoses, including tobacco use disorder, heart disease, digestive disorders, and urinary conditions. Later age ...
Any infant who consumed Nara Organics Whole Milk Organic Powdered Infant Formula and presents with constipation, poor feeding, hypotonia, loss of head control, or facial weakness should be evaluated ...
The FDA's Warning Letter identifies the SNOO X-Small and X-Large sleep sacks as unauthorized modifications to an FDA-cleared device; clinicians should caution families to discontinue use of these ...
The combination vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, AND Y) that cause the most invasive meningococcal disease cases (IMD) globally. The FDA has approved ...
The FDA has accepted for review Takeda's sBLA for IV vedolizumab in patients ages 2 and older with moderately to severely active UC or Crohn's disease; a regulatory decision is expected by Q1 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results